These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19707240)

  • 1. Hematology: Azacitidine improves survival in myelodysplastic syndromes.
    Rose MG
    Nat Rev Clin Oncol; 2009 Sep; 6(9):502-3. PubMed ID: 19707240
    [No Abstract]   [Full Text] [Related]  

  • 2. Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Peterlin P; Cluzeau T; Jullien M; Ngo Nloga AM; Calleja A; Angeli E; Chevallier P; Guillaume T; Garnier A; Le Bourgeois A; Le Gouill S; Fenaux P; Adès L; Bally C
    Br J Haematol; 2020 Aug; 190(3):461-464. PubMed ID: 32394477
    [No Abstract]   [Full Text] [Related]  

  • 3. Azacitidine: in myelodysplastic syndromes.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.
    Scott LJ
    Drugs; 2016 May; 76(8):889-900. PubMed ID: 27193945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.
    Breccia M; Molica M; Zacheo I; Alimena G
    Expert Opin Pharmacother; 2014 Aug; 15(11):1621-30. PubMed ID: 24989987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 8. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses.
    Murray C; Wereley A; Nixon S; Hua-Yung C; von Riedemann S; Kurtin S;
    Can Oncol Nurs J; 2012; 22(4):222-34. PubMed ID: 23362656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.
    Garcia JS; Swords RT; Roboz GJ; Jacoby MA; Garcia-Manero G; Hong WJ; Yang X; Zhou Y; Platzbecker U; Steensma DP; Wolff JE; Fenaux P
    Leuk Res; 2021 May; 104():106555. PubMed ID: 33705966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
    Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
    Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
    [No Abstract]   [Full Text] [Related]  

  • 11. Decitabine in myelodysplastic syndromes: viewpoints.
    Garcia-Manero G; Saba HI
    Drugs; 2006; 66(7):959-60. PubMed ID: 16740015
    [No Abstract]   [Full Text] [Related]  

  • 12. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
    Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF
    Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
    Fenaux P; Mufti GJ; Hellstrom-Lindberg E; Santini V; Finelli C; Giagounidis A; Schoch R; Gattermann N; Sanz G; List A; Gore SD; Seymour JF; Bennett JM; Byrd J; Backstrom J; Zimmerman L; McKenzie D; Beach C; Silverman LR;
    Lancet Oncol; 2009 Mar; 10(3):223-32. PubMed ID: 19230772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
    Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
    J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 17. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.
    Kamiya T; Nakazato T
    Med Oncol; 2019 Jan; 36(3):25. PubMed ID: 30706221
    [No Abstract]   [Full Text] [Related]  

  • 18. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
    Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD
    Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure.
    Prébet T; Thepot S; Gore SD; Dreyfus F; Fenaux P; Vey N
    Haematologica; 2013 Feb; 98(2):e18-9. PubMed ID: 22983576
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience.
    Kantarjian HM
    J Clin Oncol; 2002 May; 20(10):2415-6. PubMed ID: 12011118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.